The lack of lead compounds that specifically recognize and manipulate the function of RNA molecules limits our ability to consider RNA targets valid for drug discovery. Herein is reported a high-throughput biochemical screen for inhibitors of RNAprotein interactions based on AlphaScreen technology that incorporates several layers of specificity measurements into the primary screen. This screen was used to analyze approximately 5500 compounds from a collection of bioactive small molecules to detect inhibitors of the HIV-1 Rev-RRE and BIV Tat-TAR interactions. This proof-of-concept screen validates the assay as one that accurately identifies hit molecules and determines the selectivity of those hits. (Journal of Biomolecular Screening 2007: 946-955) 
INTRODUCTION
R NA MOLECULES FOLD INTO complex tertiary structures that dictate biological function. These structured RNAs are increasingly implicated in a wide range of biological processes. These molecules also represent an untapped class of potential drug targets. Specific binding of small molecules remains a significant hurdle in the validation of RNA as a drug target. Small molecules that bind to RNA, such as aminoglycosides and intercalative dyes, do so with little or no specificity. 1, 2 However, bacterial riboswitches recognize their cognate small-molecule ligands with exquisite specificity. [3] [4] [5] Therefore, finding specific RNA-binding small molecules should be possible through high-throughput screening (HTS).
To determine what chemotypes could bind to RNA, we chose a structured viral RNA element of HIV-1 known as the Rev-responsive element (RRE). The RRE is a 351-nucleotide element present on all intron-containing RNAs generated from the HIV-1 genome, able to drive nuclear RNA export through interaction with the viral Rev protein. 6, 7 The insertion of an αhelical arginine-rich motif (ARM) of Rev into the widened major groove of a stem loop within the RRE, known as RRE IIB, provides most of the driving force for this interaction. 8, 9 To simultaneously address RNA binding and selectivity, a counterscreen was established by using the transactivating response element (TAR) of bovine immunodeficiency virus (BIV). This interaction involves a similar recognition event between a widened major groove on a specific stem loop of BIV TAR and an ARM of the Tat protein. 10 However, the BIV Tat ARM adopts a β-hairpin peptide structure, thus providing a related but structurally distinct specificity control. 11 Unlike previous studies, our study focused solely on the minimal binding domains of the RNA and protein to identify molecules that specifically recognize the peptide-binding site on the RNA. 12 Biochemical methods for studying RNA-protein interactions lag behind those used to study proteins. The commonly used gel mobility-shift assay is very low throughput and requires the use of radiolabeled RNA. Recently, several solution phase assays have been developed to examine the inhibition of RNA-protein interactions. However, each of these methods has its limitations in the search for RNA-binding small molecules. 12, 13 Therefore, we developed and optimized a nonradiometric solution phase assay based on AlphaScreen technology. This assay was used to screen approximately 5500 molecules to detect inhibitors of the HIV-1 Rev-RRE interaction, the BIV Tat-TAR interaction, or both. All potential hits were validated with several secondary assays, which included the gel mobility-shift assay and surface plasmon resonance (SPR).
MATERIALS AND METHODS

Materials
All RNA constructs in this study, with or without a biotin tag, were purchased from Dharmacon Inc. (Lafayette, CO). The peptide ligands were synthesized on a Rainin Symphony Multiplex 12-column peptide synthesizer (Oakland, CA) and purified using reverse-phase high-performance liquid chromatography (HPLC) on Xterra C18 39 × 50-mm columns (Waters, Milford, MA). Reactive fluorescein derivatives 5-carboxyfluorescein succinimidyl ester and 5-iodoacetamidofluorescein were purchased from Invitrogen (Carlsbad, CA). AlphaScreen anti-FITC detection and TruHits kits (10,000 assay points) were purchased from PerkinElmer (Waltham, MA). AlphaScreen assays were conducted in 384-well white Optiplates from PerkinElmer, and fluorescence polarization assays were conducted in 384-well black microplates from Corning Life Sciences (Acton, MA). Streptavidin was purchased from Millipore (Billerica, MA). Surface plasmon resonance chips were purchased from Biacore Inc. (Piscataway, NJ). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
AlphaScreen assay
AlphaScreen assays were conducted in assay buffer: HEPES (30 mM, pH 7.5), KCl (100 mM), NaCl (40 mM), ammonium acetate (10 mM), guanidinium hydrochloride (10 mM), MgCl 2 (2 mM), EDTA (0.5 mM), DMSO (3%), Escherichia coli tRNA (Sigma, 50 µg/mL), and NP-40 (0.01%). This buffer helped minimize the adsorption of the basic peptide to the walls of the microplate. 13 The RNA constructs used were as follows: HIV-1 RRE 5′GGUAUGGGCGCAGCGCAAGCU-GACGGUACAGGCC-Biotin-′3 and BIV TAR 5′GCUCGUGU-AGCUCAUUAGCUCCGAGC-Biotin-′3. The peptides used were the following: Rev4ARC-Fl succinyl-TRQARRNRRRRWR-ERQRAAAARC-amide labeled on the C-terminal cysteine with 5-iodoacetamidofluorescein and BIV Tat-Fl fluorescein-hexanoic linker-SGPRPRGTRGKGRRIRR-OH. All assays were carried out in 384-well white polystyrene plates (PerkinElmer) in a final volume of 25 µL per well. The final concentration of AlphaScreen bead in each well was 10 µg/mL. To the microplate well, RNA and fluorescein-labeled peptide (15 µL total) were added; subsequently, the inhibitor molecule was added, and a 20-min incubation was done at room temperature. The addition of AlphaScreen bead (10 µL) was followed by a 30-min incubation before the assay was read on an EnVision Multilabel Plate Reader (PerkinElmer) outfitted with the HTS AlphaScreen module. The inhibitor must be added before the beads; if it is not, the avidity between beads hinders the inhibition assays. K d and K i values were calculated by fitting the data to a single-site binding mode with variable slope (Y = Bottom + (Top -Bottom)/(1 + 10^((LogEC 50 -X)*HillSlope))) by using Graphpad Prism software (San Diego, CA).
Fluorescence polarization
Fluorescence polarization (FP) assays were conducted in HEPES (30 mM, pH 7.5), KCl (100 mM), NaCl (40 mM), ammonium acetate (10 mM), guanidinium hydrochloride (10 mM), MgCl 2 (2 mM), EDTA (0.5 mM), DMSO (3%), and NP-40 (0.01%). Direct binding experiments between Rev4ARC-Fl and the RRE-IIB long-stem RNA construct, 5′GGACCUGGUAUGG-GCGCAGCGCAAGCUGACGGUACAGGCCAGGUCC-3′, gave a K d of 20 nM (data not shown). All FP assays were run by using 10 nM Rev peptide, and competition assays were performed with 80 nM RRE IIB (4× K d ); the concentrations of Rev peptide and RRE IIB were kept constant, and the unlabeled competitor peptide was titrated.
Assay optimization and automation
The initial screening data were generated on a screening system integrated by High Resolution Engineering (Woburn, MA) with integrated plate incubators (Liconic, Woburn, MA). Plates were transferred from instrument to instrument by using a Staubli T60 robot arm (Duncan, SC). Assay materials and AlphaScreen beads were dispensed in bulk by using Matrix Wellmates (Matrix Technologies, Hudson, NH). Compound plates were centrifuged in a Vspin plate centrifuge (Velocity11, Menlo Park, CA). All compound transfers were accomplished by using a 384-well pin tool with 10-nL hydrophobic surface-coated pins (V & P Scientific, San Diego, CA). These pins allowed for the delivery of approximately 25 nL of a DMSO solution of compound stock with typical coefficients of variation (CVs) of less than 10%. After the pertinent periods of incubation were complete, the signal was measured by using an EnVision Multilabel Plate Reader (PerkinElmer). FP assays were run by using a 480-nm excitation filter, a static and polarized 535-nm filter, and an FP FITC dual mirror. The G-factor was set to 0.8 with a gain of 250. The AlphaScreen assay used a 384-A1 aperture with no correction factors.
Gel mobility-shift assay
Oligonucleotide sequences that were used were the following: wild-type RRE IIB 5′GGUAUGGGCGCAGCGCAAGCUGACG-GUACAGGCC-3′ and BIV TAR 5′GCUCGUGUAGCUCAU-UAGCUCCGAGC-3′. RNA oligonucleotides were 32 P-labeled by using T4 polynucleotide kinase (Promega, Madison, WI) and [ 32 P] γ-ATP (PerkinElmer) according to the manufacturer's instructions and were gel-purified on a 15% denaturing acrylamide gel with 8 M urea. The bands were cut and eluted overnight in sodium acetate (600 mM, pH 6.0), EDTA (1 mM), and sodium dodecyl sulfate (SDS; 0.01%), and RNA was precipitated in 100% ethanol for 4 h. RNA was resuspended in water and analyzed by using a 15% denaturing acrylamide gel with 8 M urea to ensure that it was labeled and intact.
After the 32 P-labeled RNA oligonucleotides were purified, each type of RNA (0.4 nM) was incubated with the inhibitor and cognate peptide construct (2× K d of the peptide) BIV Tat (4 nM) and HIV-1 Rev4AR (20 nM) in HEPES (10 mM, pH 7.5), KCl (100 mM), MgCl 2 (1 mM), EDTA (0.5 mM), dithiothreitol (DTT; 1 mM), E. coli tRNA (50 µg/mL), DMSO (3%), and glycerol (10%) at 4 °C for 30 min. The relative amount of bound versus unbound 32 P-labeled RNA was resolved on a 10% native acrylamide gel run in 0.5× Tris-borate buffer (TBE) for 3 h at 225 V and imaged on a phosphoimager. All data were fit to a single-site binding mode with variable slope (Y = Bottom + (Top -Bottom)/(1 + 10^((LogEC 50 -X)*HillSlope))), and the K d values for wild-type and mutant RNAs were calculated by using Graphpad Prism software.
Surface plasmon resonance
A carboxymethyl dextran-coated gold-surface CM5 chip was activated with N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS). Subsequently, streptavidin was attached in sodium acetate buffer (10 mM, pH 4.5) at levels > 15,000 RU across all flow cells. Remaining reactive sites were blocked by reaction with ethanolamine. Both biotinylated RNA constructs were injected over the streptavidin surface at 5 µL/min until the desired amount had been captured (~1100 RU for small-molecule analytes).
Affinity analyses were performed at 25 °C by using a Biacore 3000 SPR instrument. The kinetics of association and dissociation were monitored at a flow rate of 100 µL/min in the same buffer used for the AlphaScreen assay, supplemented with ovalbumin (100 µg/mL) and P20 surfactant (0.005%). To account for injection artifacts, a series of sensorgrams was collected throughout the experiment after buffer alone was injected. Data reported are the differences in the SPR signal between the flow cell with biotinylated RNA and a reference cell without biotinylated RNA. Additional instrumental contributions to the signal were removed by subtraction of the average signal of the blank injections from the reference-subtracted signal. Triplicate injections of each analyte concentration were made, and equilibrium affinity analyses were done by using the software package Scrubber2 (Version 2.0a, BioLogic Software, Campbell, Australia).
RESULTS
AlphaScreen direct binding assay with HIV-1 Rev-RRE and BIV Tat-TAR
The AlphaScreen assay is based on the specific recognition of a biotinylated viral RNA molecule by a cognate fluoresceinlabeled peptide. The binding of these 2 labeled molecules colocalizes the donor and acceptor beads. The sample is irradiated with 680-nm laser light, and this irradiation results in the emission of singlet oxygen by the donor bead. The transfer of singlet oxygen from the donor to the acceptor results in the acceptor bead's luminescence at 580 to 620 nm. Initial binding experiments involving both RNA-protein interactions consisted of an independent titration of both binding partners; these data are summarized in Figure 1A and 1B. The optimal peptide concentration was 10 nM for HIV-1 Rev and BIV Tat; lower concentrations resulted in the generation of lower maximal signals, and higher concentrations are further away from physiological binding constants.
Using these peptide concentrations, we determined the K d values by titrating the respective RNA molecules (Fig. 1C) . The observed binding constants were 6 nM for HIV-1 RRE and 2 nM for BIV Tat; these constants were in good agreement with those described in earlier reports. 9, 10 Further competition assays were set up using RNA concentrations, which resulted in roughly 80% maximal signal and thus 5 nM BIV TAR and 10 nM HIV-1 RRE.
Competition assays with known inhibitors
For our assay to be useful in the search for previously unknown inhibitors of RNA-protein interactions, the assay must detect known inhibitors. Competition binding assays were performed both with unlabeled peptides and a known inhibitor of the Rev-RRE interaction. Figure 2 shows the results of these assays. The unlabeled cognate peptides efficiently competed for binding, whereas the negative control peptides either did not compete for RNA binding (BIV Tat binding to HIV-1 RRE) or nonspecifically interacted at a significantly higher concentration (Rev binding to BIV TAR). The assay detected the inhibition of the RNA-protein interaction by a small molecule (3,6 diaminoacridine). 14 Surprisingly, this acridine showed a roughly 10-fold specificity between the 2 different RNA molecules. The signal-to-noise ratios were 25:1 for Rev-RRE and 100:1 for BIV Tat-TAR.
Comparison to FP assays and effect of tRNA
Previous screens for inhibitors of RNA-protein interactions have focused mainly on fluorescence techniques such as FP. Although this method was a radiation-free assay that was easily miniaturized, it had several flaws. The Z′ for this assay was relatively low, around 0.5. This was due to a relatively small change in polarization (∆mp) of 50 while competing off the fluorescently labeled probe. This modest change in polarization was only attainable by conducting the assay with a significantly longer portion of the RRE and at RNA concentrations 4-fold over the observed K d . This high RNA concentration was necessary to maintain the maximal signal change, and it further supports the need for an alternative assay. Other flurophores and linker constructs were tested for the peptide probe and did not show improvement over the original labeled peptide (data not shown). In addition, using a large excess of tRNA disrupted the binding interaction. The inability to include excess oligonucleotide prevented the differentiation between high-affinity, low-specificity binding interactions and high-affinity, highspecificity binding interactions (Fig. 3A) . This inability poses a serious potential problem with molecules that bind through intercalation or electrostatics. In contrast to the FP assay, the AlphaScreen assay easily tolerated at least a 50-fold excess of tRNA. The presence of tRNA allowed for efficient discrimination of specific from nonspecific binding modes (Fig. 3B) .
Optimization of the high-throughput assay
Before we used this assay in HTS, several critical assay parameters were optimized. First, location-dependent effects from the AlphaScreen signal were measured over the entire microplate. Figure 4A and 4B illustrates the drift in 3 levels of signal over the entire plate. Signal from row 1 was consistently low (wells 1-16 in red); therefore, no compounds were included in this row. Second, we examined the effect of DMSO on the assay signal. Figure 4C illustrates that the signal was stable in the presence of DMSO at concentrations up to 5%; at DMSO concentrations greater than 5%, the signal decreased sharply. Finally, to maximize the signal-to-noise ratio while minimizing the overall time needed to perform the assay, we examined the effect of equilibration time. The signal-to-noise ratio for HIV-1 RRE was maximal with a 30-min incubation, whereas the BIV Tat-TAR interaction did not reach the maximum until 60 min (Fig. 4D) . A 30-min equilibration time was used to optimize for the RRE target, which had the lower overall signal-to-noise ratio.
Primary screen
A small collection of molecules (~5500) with known bioactivities, including several therapeutic molecules approved by the Food 
FIG. 3.
Greater ability to measure specific binding in the AlphaScreen than in the fluorescence polarization (FP) assay. Specific binding of Revlike peptides requires helical secondary structure in the peptide. 9 (A) The FP assay was unable to discriminate the specific from the nonspecific, whereas the AlphaScreen assay (results in B) ) easily detected the actual difference in binding. and Drug Administration (FDA), was used in pilot screens with the AlphaScreen assay. The compound library was screened at a fixed concentration (10 µM) against HIV-1 RRE, BIV TAR, and the AlphaScreen Tru-Hits assay, which monitored direct interaction between the AlphaScreen beads. The scatterplots for percentage inhibition of the library versus all 3 targets are shown in Figure 5A to 5C. We included 8 positive controls (cognate peptide at a concentration of 3 µM) and negative controls (DMSO) located at the plate's edge and in the plate's center to examine possible edge effects. Overall, the quality of data related to both RNA targets was quite good. The average Z′ factor was 0.60 for RRE and 0.76 for TAR. A slight edge effect greater than that observed in the initial optimization experiments was apparent. This edge effect was most likely due to a small temperature gradient across the plate, which was stored in the incubator.
We examined all compounds above the 99% quantile in terms of activity on either RNA target that did not show significant (greater than 99% quantile) activity in the Tru-Hits assay, and then we filtered for duplicates and problematic chemotypes. An example molecule that interfered with the AlphaScreen signal generation and was therefore filtered out is highlighted with the red arrow in Figure 5A to 5C. This analysis resulted in 32 putative hit molecules.
All 32 compounds were assayed to establish potency against both RNA targets. Only one third of the molecules exhibited saturable dose-response curves with K i values less than 10 µM and Hill slopes approaching 1.0 on either target. These molecules were designated as validated hits.
It should be noted that our compound library contained multiple copies of neomycin B, which is an aminoglycoside antibiotic and a commonly cited inhibitor of the Rev-RRE interaction. 15 Neomycin B did not significantly inhibit either RNA-protein interaction. Interestingly, when tested without the addition of tRNA, neomycin B inhibited the Rev-RRE interaction with a K i of 5 µM. This result exemplifies the utility of the AlphaScreen assay and the use of tRNA in the binding buffer, as it allows for the upfront discrimination between specific and nonspecific RNA-binding molecules.
Secondary assays
The 10 validated hits were subjected to several secondary assays to confirm the initial results and address selectivity. The process included 2 distinct biochemical secondary assays: the gel mobility-shift assay and SPR.
The gel mobility-shift assay, standard within the field, allows the determination of K d by using the interaction of a native unlabeled RNA-protein interaction. SPR analysis, with biotinylated RNA attached to a streptavidin-labeled flow cell, allows direct examination of RNA binding, whereas almost all other assays detect inhibition of the RNA-protein complex.
Of the 10 validated hits, only 4 were competent in both the gel mobility-shift assay and the SPR analysis. The other 6, all from 1 chemotype, had no activity in either assay. Exemplary data, chemical structure, and name are shown in Figure 6A to 6D.
Molecules similar to suramin ( [3] in Fig. 6 ) and the suramin analog NF110 ( [4] in Fig. 6 ) have previously been shown to inhibit the Rev-RRE interaction. However, they do so by binding to the arginine-rich Rev protein/peptide as shown by earlier SPR studies; this finding was corroborated in our studies (data not shown). 12 The glutathione analog ( [2] in Fig. 6 ) inhibited both the Rev and BIV Tat interactions in the gel mobility-shift assay; the K i was 10 µM in the AlphaScreen assay and greater than 50 µM in the gel mobility-shift assay (data not shown).
The molecule with the best affinity and selectivity profile between the 2 RNA targets was propidium iodide ( [1] in Fig. 6 ). Propidium iodide ( [1] in Fig. 6) is a non-cell-permeant DNA intercalator commonly used in fluorescence-activated cell sorter (FACS) analysis as a means of identifying necrotic cells. 16 Gelshift results for ( [1] in Fig. 6 ) are shown in Figure 6B . Propidium iodide ( [1] in Fig. 6 ) showed a 5-fold difference in its binding specificity for the 2 RNA targets ( Fig. 6C) and had a K i of approximately 5 µM against the RRE target in all 3 assays. The SPR results for ( [1] in Fig. 6 ) are shown in Figure 6D .
DISCUSSION
Although the study of RNA-small molecule ligand interactions is still in its infancy, knowledge about the biological processes in which RNA plays a role is ever expanding. Using HTS to identify previously unknown, specific inhibitors of RNA-protein interactions will be of great importance in stimulating future study. Prior work has looked at exploiting the chemical moieties known to interact with RNA: guanidinium groups, 17 intercalative moieties, 18 aminoglycosides, 19 or any combination of the 3. It is apparent that specificity remains the utmost challenge.
Reported herein is an HTS-compatible assay that includes multiple layers of specificity measurements. First, the assay includes a large excess of tRNA in the buffer to suppress the effects of molecules with general RNA-binding characteristics. This strategy allowed the elimination of neomycin B from the initial hit list. Second, the method simultaneously counterscreened 2 related but structurally distinct RNA targets. This approach focused subsequent efforts on chemotypes active in only the system of interest. Finally, orthogonal detection methods were used in secondary screening to eliminate artificial binding induced by the label or assay system.
The inhibitors of RNA-protein interactions that were identified in this proof-of-concept screen serve to validate the assay as both a method of identifying hit molecules and of eliminating many artifacts and nonspecific molecules. Although the current hits do not represent reasonable small-molecule leads for further structure-activity studies, they do provide an interesting glimpse into RNA affinity and specificity.
Propidium iodide is known to intercalate into DNA and, to a lesser extent, into RNA. However, the inclusion of tRNA provided no apparent difference in the K i (data not shown). Therefore, it seems that propidium iodide's ability to intercalate into RNA is dependent on tertiary structure. The ability of known nucleic acid intercalators such as ethidium bromide and elatin to recognize the RRE with a reasonable specificity has previously been reported. 20 Together, our result and this previous finding imply that an intercalative binding mode does not denote a nonspecific interaction. Rather, an RNA molecule with a distinct tertiary structure may be able to recognize particular intercalators that are too bulky to fit into the grooves of generic nucleic acid secondary structure.
In conclusion, the AlphaScreen assay platform provides the ability to focus on the minimal biologically relevant RNA-protein interaction, to incorporate multiple layers of specificity determination into the screening process, and to acquire high-quality data at a rate of tens of thousands of data points per day. The assay is superior to the previously reported FP assay on the basis of the observed quality of the data that the assay yielded and an ability to permit the incorporation of a specificity control. Although the scintillation proximity assay (SPA) allowed for the screening of several hundred thousand molecules, it does require radiolabeled RNA, which adds a layer of practical complexity. 12 Also, the AlphaScreen assay described herein focuses on the high-affinity binding site between minimal peptide and RNA constructs, thus increasing the probability of identifying novel chemotypes able to specifically recognize the peptide binding site on the RRE. It is our hope that these novel chemotypes will expand our knowledge of RNA-ligand interactions.
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FIG. 5.
Percentage inhibition scatterplots for both RNA targets and the Tru-Hits kit. Positive controls are in green, negative controls are in red, and screening compounds are in black. The blue and purple lines depict the 5% to 95% and 1% to 99% quantiles of the distribution of screening compound activities and approximately correspond to significance at p = 0.05 and p = 0.01 levels for the null hypothesis that the measured activity is due solely to experimental variation. Because the Tru-Hits assay lacks a positive control, the mean high signal for each plate in this experiment was set to reflect the average signal to noise observed from the RNA assays. Only compounds with highly significant activity in the RNA assay (above the 99% quantile) but lacking significant activity for Tru-Hits (within the 1%-99% quantiles) were considered in a subsequent secondary analysis. An example compound that inhibits the Tru-Hits assay and was therefore not further examined is highlighted with the red arrow. (FIG. 5. continued) FIG. 6. Validated hits from the initial screen and representative secondary data using propidium iodide (1) as an example. (A) The chemical structures of the hits for either 1 or both of the RNA-peptide targets. Gel-shift analysis (B) illustrating the ability of 1 to inhibit the Rev-RRE complex formation. AlphaScreen dose-response data are shown in (C) against both the Rev-responsive element (RRE; red) and bovine immunodeficiency virus (BIV) transactivating response element (TAR) (blue). (D) Surface plasmon resonance (SPR) sensorgrams for propidium iodide (1) binding to immobilized RRE.
